CoChat

Implications of Ozempic and Other GLP-1 Receptor Agonists for Facial Plastic Surgeons

Open access
Humphrey, Clinton D., Lawrence, Anna C. · 2023 · Facial Plastic Surgery
Cited by 77

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Obesity is a growing global health concern. Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Ozempic, have emerged as potential treatments. GLP-1 receptor agonists regulate appetite and can promote weight loss. Some GLP-1 receptor agonists, though Food and Drug Administration (FDA)-approved for diabetes, are also used off-label for weight loss alone. Rapid weight and fat loss with these medications can lead to what has been called “Ozempic Face” on social media and in the lay press, where facial volume and fat are depleted, resulting in wrinkles and sagging skin. Prescribers rarely counsel patients about the potential impact on the face, and the plastic surgery community faces a challenge in managing the facial changes associated with rapid weight loss. Dermal fillers, skin tightening techniques, and surgical interventions are useful for both restoration of facial volume and to manage excess skin. Discontinuation of GLP-1 receptor agonists should be considered prior to general anesthesia due to delayed gastric emptying while on these medications. As the popularity of GLP-1 receptor agonists grows, facial plastic surgeons must be aware of both the impact on facial appearance and perioperative considerations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1055/a-2148-6321

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 5

  1. M Suran, 2023, As Ozempic's popularity soars, here's what to know about semaglutide and weight loss, JAMA, 329, 1627, 10.1001/jama.2023.2438 · DOI · Paper page
  2. D Rubino, 2021, Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial, JAMA, 325, 1414, 10.1001/jama.2021.3224 · DOI · Paper page
  3. R A Couto, 2015, Objective assessment of facial rejuvenation after massive weight loss, Aesthetic Plast Surg, 39, 847, 10.1007/s00266-015-0540-6 · DOI
  4. R A Couto, 2019, Facelift in patients with massive weight loss, Clin Plast Surg, 46, 559, 10.1016/j.cps.2019.05.003 · DOI
  5. E Harris, 2023, Oral semaglutide led to similar weight loss as injection, company says, JAMA, 329, 2011, 10.1001/jama.2023.9601 · DOI

Cited by

Metadata

Authors
Humphrey, C. D., & Lawrence, A. C.
Venue
Facial Plastic Surgery
Published
2023-08-04
Volume
39
Issue
06
Pages
719-721
ISSN
  • 0736-6825 (ISSN-L)
  • 1098-8793
OpenAlex
W4385566892
Cited by
77
References
1
FWCI
17.50
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.